Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Dec;8(24):1701.
doi: 10.21037/atm-20-4438.

Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind?

Silvia Catanese  1   2 , Florian Lordick  2
Affiliations
Editorial

Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind?

Silvia Catanese et al. Ann Transl Med. 2020 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure from (available at http://dx.doi.org/10.21037/atm-20-4438). FL reports personal fees from Amgen, personal fees from Astellas, personal fees from Astra Zeneca, personal fees from Biontech, grants and personal fees from BMS, personal fees from Eli Lilly, personal fees from Elsevier, personal fees from Excerpta Medica, personal fees from Imedex, from Infomedica, grants and personal fees from Iomedico, personal fees from Medscape, from MedUpdate, personal fees from Merck Serono, personal fees from Merck Sharp Dohme, personal fees from Oncovis, personal fees from Promedicis, personal fees from Springer Nature, personal fees from StreamedUp!, from Zymeworks, personal fees from Bayer, personal fees from Roche, outside the submitted work. The other author has no conflicts of interest to declare.

Comment on

References

    1. Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol 2020;21:571-80. 10.1016/S1470-2045(20)30011-5 - DOI - PubMed
    1. Chen X, Ma L, Wang X, et al. Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210. Cancer Biol Med 2019;16:173-81. 10.20892/j.issn.2095-3941.2018.0172 - DOI - PMC - PubMed
    1. Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2020;21:832-42. 10.1016/S1470-2045(20)30110-8 - DOI - PubMed
    1. Ringelhan M, Pfister D, O’Connor T, et al. The immunology of hepatocellular carcinoma. Nat Immunol 2018;19:222-32. 10.1038/s41590-018-0044-z - DOI - PubMed
    1. NCI Drug Dictionary [Internet]. National Cancer Institute. 2011. Available online: https://www.cancer.gov/publications/dictionaries/cancer-drug